On July 27, 2026 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported Lumara Bio as a dedicated oncology therapeutics division that combines ITM’s existing pipeline and the internal teams supporting its development and commercialization.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Lumara Bio will operate as a defined division within ITM to focus key resources toward commercial readiness for its most advanced drug candidate, 177Lu-edotreotide (ITM-11), which is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of August 28, 2026, alongside its broader early- and late-stage drug development activities.
"As we approach ITM-11’s PDUFA date, creating the Lumara Bio division enables us to focus our internal efforts and create a structure around the teams responsible for a potential commercial launch," said Dr. Andrew Cavey, chief executive officer of ITM. "In addition, Lumara Bio reflects the evolution of the two pillars of ITM’s business and builds on our deep expertise in isotope manufacturing and supply as well as our proven track record in radiopharmaceutical development. Lumara Bio is uniquely positioned to address the growing need for radiopharmaceutical innovation by accelerating progress across our targeted radiopharmaceutical pipeline and expanding our portfolio."
Beyond 177Lu-edotreotide, Lumara Bio will advance ITM’s diverse pipeline of targeted radiopharmaceutical candidates spanning multiple cancer types, treatment approaches, and proprietary isotope platforms, with the goal of bringing innovative radiopharmaceutical therapies to more patients. The division builds on ITM’s scientific foundation and isotope expertise, as well as its radiopharmaceutical development and strategic scientific collaborations. Lumara Bio will leverage ITM’s isotope manufacturing and supply services to support its pipeline and potential commercial launch activities.
177Lu-edotreotide is currently under regulatory review by the U.S. Food and Drug Administration and is not approved by any regulatory authority for any use.
(Press release, ITM Isotopen Technologien Munchen, JUL 27, 2026, View Source [SID1234669448])